These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19937037)

  • 1. [Treatment recommendations for psoriatic arthritis].
    Boehncke WH
    Z Rheumatol; 2009 Dec; 68(10):842-4. PubMed ID: 19937037
    [No Abstract]   [Full Text] [Related]  

  • 2. EULAR PsA management recommendations 2019: can the recommendations be improved?
    Fleischmann RM
    Ann Rheum Dis; 2020 Jun; 79(6):680-682. PubMed ID: 32434811
    [No Abstract]   [Full Text] [Related]  

  • 3. [Spondyloarthritis including psoriatic arthritis].
    Krause A; Märker-Hermann E
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2031-3. PubMed ID: 23023616
    [No Abstract]   [Full Text] [Related]  

  • 4. Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?
    Mease PJ
    Nat Rev Rheumatol; 2012 May; 8(5):251-2. PubMed ID: 22549279
    [No Abstract]   [Full Text] [Related]  

  • 5. Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: A cross-sectional analysis.
    Lucasson F; Balanescu A; Kiltz U; Leung YY; Aydin SZ; Gaydukova I; Lubrano E; Coates LC; de Wit M; Orbai AM; Gossec L
    Joint Bone Spine; 2022 Oct; 89(5):105372. PubMed ID: 35257864
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review.
    Acosta Felquer ML; Coates LC; Soriano ER; Ranza R; Espinoza LR; Helliwell PS; FitzGerald O; McHugh N; Roussou E; Mease PJ
    J Rheumatol; 2014 Nov; 41(11):2277-85. PubMed ID: 25362711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Psoriatic arthritis : Overview of drug therapy options and administration characteristics].
    Behrens F; Thaçi D; Wollenhaupt J; Krüger K
    Hautarzt; 2017 Feb; 68(2):153-169. PubMed ID: 28083597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint count reliability in psoriatic arthritis observational trials--an unreported problem.
    Tillett W; Shaddick G; Korendowych E; de Vries CS; McHugh N
    Rheumatology (Oxford); 2012 Jul; 51(7):1333-4. PubMed ID: 22562935
    [No Abstract]   [Full Text] [Related]  

  • 9. Late-onset psoriatic arthritis in Japanese patients.
    Yamamoto T; Ohtsuki M; Sano S; Morita A; Igarashi A; Okuyama R; Kawada A
    J Dermatol; 2019 Feb; 46(2):169-170. PubMed ID: 30614050
    [No Abstract]   [Full Text] [Related]  

  • 10. Psoriatic arthritis in 2015: Advancement continues in imaging, tight control and new drugs.
    Olivieri I; D'Angelo S
    Nat Rev Rheumatol; 2016 Feb; 12(2):76-8. PubMed ID: 26794864
    [No Abstract]   [Full Text] [Related]  

  • 11. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis.
    Coates LC; Gossec L; Ramiro S; Mease P; van der Heijde D; Smolen JS; Ritchlin C; Kavanaugh A
    Rheumatology (Oxford); 2017 Aug; 56(8):1251-1253. PubMed ID: 28077693
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of methotrexate in psoriatic arthritis: what is the evidence?
    Ianculescu I; Weisman MH
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S94-7. PubMed ID: 26470718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The therapeutic benefits of systemic treatment of psoriatic arthritis? The example of golimumab in psoriatic arthritis].
    Boulinguez S; Sibilia J
    Ann Dermatol Venereol; 2011 May; 138(5 Suppl 1):H11-5. PubMed ID: 21703459
    [No Abstract]   [Full Text] [Related]  

  • 14. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
    [No Abstract]   [Full Text] [Related]  

  • 15. [Gold preparations in therapy of rheumatoid and psoriatic arthritis].
    Nasonova VA; Lukina GV; Sigidin IaA; Badokin VV
    Ter Arkh; 2003; 75(5):88-90. PubMed ID: 12847908
    [No Abstract]   [Full Text] [Related]  

  • 16. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options.
    Turkiewicz AM; Moreland LW
    Arthritis Rheum; 2007 Apr; 56(4):1051-66. PubMed ID: 17393414
    [No Abstract]   [Full Text] [Related]  

  • 17. New drugs for peripheral joint psoriatic arthritis.
    Drug Ther Bull; 2006 Jan; 44(1):1-5. PubMed ID: 16425898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
    Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
    Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.
    Reygaerts T; Mitrovic S; Fautrel B; Gossec L
    Joint Bone Spine; 2018 Jul; 85(4):405-410. PubMed ID: 29452303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development.
    Leijten EF; Radstake TR; McInnes IB; Jacobs JW
    Expert Rev Clin Immunol; 2019 May; 15(5):441-444. PubMed ID: 30729823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.